Abstract 1464P
Background
In recent years, the use of systemic anticancer therapy (SACT) includes molecular targeting agents (MTAs) and immune-checkpoint inhibitors (ICIs) tend to extend overall survival in advanced cancer patients. But the life expectancy in patients with advanced cancer who have discontinued SACT was unclear.
Methods
We analyzed 700 patients who died of advanced cancer from August 2011 to August 2019 retrospectively at Mitsubishi Kyoto Hospital. The primary endpoint of this study was to identify clinical factors of the survival time from the last administration to death by using the Cox-proportional Hazard model. The clinical factors were analyzed using age, sex, the primary site of cancer, metastatic site of cancer, the use of MTAs, and the use of ICIs.
Results
As a background, the median age is 73 years old, 391 males, 309 females, 145 gastroesophageal cancers, 137 biliary pancreatic cancers, 13 hepatocellular carcinomas, 118 colorectal cancer, 127 lung cancers, 44 breast cancers, 25 urological malignancies, 35 gynecological malignancies, 17 head, and neck cancer. In a multivariate analysis, age (Hazard Ratios 0.823, 95% Confidential Interval 0.698-0.970), colorectal cancer (HRs 0.710, 95%CI 0.518-0.974), peritoneal metastasis (HRs 1.405, 95%CI 1.156-1.707) and the use of ICIs (HRs 2.660, 95%CI 1.727-4.098) were independent clinical factors. The median survival time from the last administration of SACT to death was 89 days in all patients, 104 in over 73 years old patients, 114 with colorectal cancer, 77 with peritoneal metastasis, and 54 in the use of ICIs.
Conclusions
Age, colorectal cancer, peritoneal metastasis, and the use of ICIs were significant associated factors of expecting time from the last administration of SACT to death. Information on these factors may aid clinical decision-making in referral to palliative care institutes. Information on these predictors is useful to explain the timing of referral to palliative care institutes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.